{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-011233","form_type":"8-K","ticker":"NSPR","cik":"0001433607","company_name":"InspireMD, Inc.","filed_at":"2024-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.174848+00:00","generated_at":"2026-06-04T07:47:31.438050+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"InspireMD's C-GUARDIANS 12-month abstract accepted for LINC 2024; prior 30-day DSMI 0.95%","bullets":["Abstract of 12-month outcomes from C-GUARDIANS trial (316 patients, 24 sites) accepted for LINC 2024 (May 28-31, Leipzig).","Previously reported 30-day DSMI rate of 0.95% (ITT) and 0.63% (per-protocol).","Positive 12-month data could support PMA submission later in 2024 and potential U.S. launch of CGuard Prime in H1 2025.","Trial evaluates CGuard Carotid Stent System for carotid artery stenosis; primary endpoint includes death, stroke, MI through 365 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-011233","json":"https://secwatch.observer/filing/0001493152-24-011233.json","markdown":"https://secwatch.observer/filing/0001493152-24-011233.md","text":"https://secwatch.observer/filing/0001493152-24-011233.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1433607/000149315224011233/0001493152-24-011233-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1433607/000149315224011233/from8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:47:31.438050+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}